Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage

Background: Patients with traumatic intracranial hemorrhage (TIH) anticoagulated with warfarin are at an increased risk of mortality. Fresh frozen plasma (FFP) and vitamin K have been the standard treatment for warfarin reversal; however, guidelines now recommend the use of prothrombin complex concentrate (PCC) for warfarin reversal in patients with life-threatening bleeding. Our protocol uses one vial (w1000 units) of activated PCC (aPCC) for warfarin reversal, regardless of the weight or presenting international normalized ratio (INR). The purpose of this study was to determine the safety and efficacy of using fixed, low-dose aPCC for warfarin reversal in patients with TIH. Methods: This was a retrospective chart review that included patients with an Abbreviated Injury Scale Head score of >= 3, TIH, and initial INR >= 1.5 on warfarin. Patients aged < 18 years and those with no repeat INR were excluded. The primary outcome was to compare the percentage of patients with INR < 1.4 after receiving aPCC versus FFP within 24 hours. Results: Eighty-nine patients were in the FFP group and 31 patients in the aPCC group. The INR was reversed more effectively in the aPCC group compared with the FFP group (90.3% versus 69.7%, P = 0.029). The median time (hours) to reversal was also significantly shorter in the aPCC group compared with the FFP group (3.75 versus 6.75, P = 0.003). However, there was no difference in mortality (35.5% aPCC versus 22.2% control, P = 0.162) or incidences of thrombosis. Conclusion: Fixed, low-dose aPCC is safe and more effective at reversing the effects of warfarin than FFP in patients with TIH. (C) 2017 Elsevier Inc. All rights reserved.